What are the risks of using Paxlovid (nirmatrelvir/ritonavir) and Tikosyn (dofetilide) together?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Paxlovid and Tikosyn: A Potentially Life-Threatening Drug Interaction

Concomitant use of Paxlovid (nirmatrelvir/ritonavir) and Tikosyn (dofetilide) is absolutely contraindicated due to the high risk of life-threatening cardiac arrhythmias.

Mechanism of Interaction

Paxlovid contains ritonavir, which is a potent inhibitor of CYP3A4 enzymes. This creates a significant drug interaction concern with medications metabolized by this pathway, including Tikosyn (dofetilide).

  • Ritonavir strongly inhibits CYP3A4, which is responsible for the metabolism of approximately 60% of available medications 1
  • When CYP3A4 is inhibited, plasma concentrations of dofetilide can increase dramatically
  • Elevated dofetilide levels significantly increase the risk of QT prolongation and potentially fatal cardiac arrhythmias, including Torsades de Pointes

Clinical Implications

The FDA drug label for Paxlovid explicitly addresses this interaction:

  • Antiarrhythmics (including dofetilide) are listed among medications contraindicated with Paxlovid 2
  • The label specifically warns that co-administration is contraindicated due to the potential for cardiac arrhythmias 2

Alternative Approaches

For patients requiring COVID-19 treatment who are on Tikosyn:

  1. Consider alternative COVID-19 treatments:

    • Remdesivir (intravenous) may be an option as it has fewer drug interactions
    • Molnupiravir might be considered, though it has lower efficacy than Paxlovid 3
  2. Temporary medication management options:

    • Temporarily discontinuing Tikosyn may be considered in some cases, but only under close cardiac monitoring and with specialist consultation
    • This approach carries significant risks and should only be undertaken with cardiology guidance

Risk Assessment and Monitoring

If a patient has inadvertently taken both medications together:

  • Immediate ECG monitoring for QT prolongation
  • Electrolyte monitoring and correction (particularly potassium and magnesium)
  • Cardiac monitoring in a hospital setting may be necessary
  • Consider measuring dofetilide plasma levels if available

Similar High-Risk Interactions with Paxlovid

Other medications that are similarly contraindicated with Paxlovid include:

  • Other antiarrhythmics: amiodarone, dronedarone, flecainide, propafenone, quinidine 2
  • Antianginals: ranolazine 2
  • Alpha-1 adrenoreceptor antagonists: alfuzosin 2

Conclusion

The interaction between Paxlovid and Tikosyn represents a serious, potentially fatal drug interaction that must be avoided. The decision to use Paxlovid must always include a thorough medication review, with particular attention to medications with narrow therapeutic indices that are metabolized by CYP3A4, such as Tikosyn.

When treating COVID-19 in patients on Tikosyn, alternative therapies should be strongly considered, and any medication changes should be made only under specialist guidance with appropriate monitoring.

References

Research

Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2022

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.